Therapeutics News and Research

RSS

Fairjourney Biologics establishes Scientific Advisory Board

FairJourney Biologics S.A., leaders in the discovery and optimization of antibodies, today announced it has established a Scientific Advisory Board (SAB) to support its strategy for ongoing growth and innovation.

16 Dec 2024

Study reveals tumor and immune cell interactions in craniopharyngiomas

Craniopharyngiomas are brain tumors that negatively impact the hormonal function of the nearby pituitary.

16 Dec 2024

Australian research unlocks new path for cancer immunotherapy

Australian-led research is unlocking new ways for immunotherapy to better target cancer.

14 Dec 2024

ZEST trial fails to meet enrollment goals for ctDNA testing in breast cancer

The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients positive for ctDNA, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

14 Dec 2024

Machine learning model predicts CDK4/6 inhibitor effectiveness in metastatic breast cancer

A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either clinical or genomic data in predicting which patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer would have better outcomes from adding CDK4/6 inhibitors to endocrine therapy as first-line treatment, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

14 Dec 2024

Adjuvant anthracycline- plus taxane-based chemotherapy regimen improves survival in high-risk breast cancer patients

Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when treated with adjuvant anthracycline- plus taxane-based chemotherapy regimens compared with those receiving adjuvant taxane-based chemotherapy regimens alone, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

14 Dec 2024

TTUHSC researcher to uncover mechanisms that regulate gene expression in Alzheimer's disease

More than six million Americans are affected by Alzheimer's disease, a form of dementia marked by accumulation of amyloid-β within the brain. Amyloid-β is a relatively small protein that forms toxic plaques in the brain contributing to the harmful effects of Alzheimer's disease.

14 Dec 2024

Study links intermittent fasting to slower hair growth

Intermittent fasting has proven benefits for metabolic health, but a new study shows that it could slow hair growth - at least in mice.

13 Dec 2024

Potential new mRNA-based therapy for pre-eclampsia

Lipid nanoparticles targeting VEGF mRNA show promise in treating pre-eclampsia, restoring maternal blood pressure and enhancing fetal health in murine models.

13 Dec 2024

New funding for innovative dementia vaccine research

Alzheimer's disease and frontotemporal dementia are devastating disorders that emerge following the buildup of misfolded proteins in the brain.

13 Dec 2024

Mediterranean plants show promise for cardiovascular disease treatment

A study initiated from a final degree project at the Universitat Autònoma de Barcelona, with the involvement of researchers from the INc-UAB, the University of Barcelona and Cuban and Chilean institutions, has resulted in an exhaustive bibliographic review of a group of Mediterranean plants, whose active principles are attributed pharmacological actions in the field of cardiovascular diseases most affecting the population.

12 Dec 2024

Deep Science Ventures and General Inception collaborate to create fibrosis-focused therapeutics company

Deep Science Ventures, a UK-based venture studio, and General Inception, a US-based venture studio, today announced a collaboration to create a company focused on developing novel treatments for fibrosis.

12 Dec 2024

Common brain network connected to heterogeneous patterns of brain atrophy in schizophrenia

A new study led by investigators from Mass General Brigham has identified a unique brain network that links varied patterns of brain atrophy, or shrinkage, associated with schizophrenia.

12 Dec 2024

New tool accelerates drug discovery

The development of molecules to study and treat disease is becoming increasingly burdened by the time and specificity required to analyze the vast amounts of data generated by synthesizing large collections of new molecules.

12 Dec 2024

Caltech develops microrobots for precise drug delivery

In the future, delivering therapeutic drugs exactly where they are needed within the body could be the task of miniature robots. Not little metal humanoid or even bio-mimicking robots; think instead of tiny bubble-like spheres.

11 Dec 2024

Groundbreaking research offers hope for pregnant people with pre-eclampsia

Penn Engineers have made a critical breakthrough that bridges a major healthy equity gap for pregnant people with pre-eclampsia, a condition that arises due to insufficient blood flow to the placenta and results in high maternal blood pressure and restricted blood flow to the fetus.

11 Dec 2024

New class of antivirals shows promise against multiple viruses

The arrival of Paxlovid in December 2021 marked another turning point in the COVID-19 pandemic - an effective antiviral that has since successfully treated millions.

11 Dec 2024

Imlunestrant offers new hope for ER-positive HER2-negative breast cancer

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, HER2-negative advanced breast cancer - as monotherapy in patients with ESR1 mutations and as combination therapy with abemaciclib (Verzenio) in all patients, regardless of ESR1 mutation status - according to results from the phase III EMBER-3 clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

11 Dec 2024

Interim analysis of STOMP study finds no efficacy for tecovirimat in mild to moderate Mpox cases

The antiviral drug tecovirimat did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate clade II mpox and a low risk of developing severe disease, according to an interim data analysis from the international clinical trial called the Study of Tecovirimat for Mpox (STOMP).

10 Dec 2024